![The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction | Current Diabetes Reports The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction | Current Diabetes Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs11892-020-01343-7/MediaObjects/11892_2020_1343_Fig2_HTML.png)
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction | Current Diabetes Reports
![Dr Reddys Laboratories: Dr Reddy's Laboratories launches Icosapent Ethyl Capsules in US - The Economic Times Dr Reddys Laboratories: Dr Reddy's Laboratories launches Icosapent Ethyl Capsules in US - The Economic Times](https://img.etimg.com/thumb/width-1200,height-900,imgsize-10766,resizemode-75,msid-83738741/industry/healthcare/biotech/pharmaceuticals/dr-reddys-laboratories-launches-icosapent-ethyl-capsules-in-us.jpg)
Dr Reddys Laboratories: Dr Reddy's Laboratories launches Icosapent Ethyl Capsules in US - The Economic Times
South Carolina Society of Health-System Pharmacists - ⚠️ “A new indication was awarded on Dec. 13, 2019, for Vascepa® (icosapent ethyl - Amarin) capsules. In combination with the highest tolerated dose of
![These highlights do not include all the information needed to use ICOSAPENT ETHYL CAPSULES safely and effectively. See full prescribing information for ICOSAPENT ETHYL CAPSULES. ICOSAPENT ETHYL capsules, for oral useInitial U.S. These highlights do not include all the information needed to use ICOSAPENT ETHYL CAPSULES safely and effectively. See full prescribing information for ICOSAPENT ETHYL CAPSULES. ICOSAPENT ETHYL capsules, for oral useInitial U.S.](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-01.jpg&id=700018)
These highlights do not include all the information needed to use ICOSAPENT ETHYL CAPSULES safely and effectively. See full prescribing information for ICOSAPENT ETHYL CAPSULES. ICOSAPENT ETHYL capsules, for oral useInitial U.S.
![Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study - Budoff - 2018 - Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study - Budoff - 2018 -](https://onlinelibrary.wiley.com/cms/asset/59a17799-4cd2-4f46-bdeb-a675b505f641/clc22856-fig-0001-m.jpg)